Arrowhead Pharmaceuticals AI Stock Analysis
Arrowhead Pharmaceuticals (HDP1) AI Stock Analysis
Arrowhead Pharmaceuticals
(XETRA:HDP1)
No summary available
Arrowhead Pharmaceuticals (HDP1) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 6.75B
- Dividend Yield
- ―
- Average Volume (3M)
- 298
- Price to Earnings (P/E)
- -9.4
- Beta (1Y)
- 0.83
- Revenue Growth
- -49.15%
- EPS Growth
- -5757.84%
- Country
- Germany
- Employees
- 1,059
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Arrowhead Pharmaceuticals Business Overview & Revenue Model
Company Description
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. Th...
Arrowhead Pharmaceuticals Earnings Call Summary
The call was predominantly optimistic, with strong REDEMPLO prescription and prescriber growth, broadening payer coverage, positive pivotal sHTG efficacy results, clinical validation of new RNAi delivery capabilities and improved financing terms. These positives were tempered by a substantial net loss, lower year-over-year revenue, higher operating expenses, ongoing prescription-to-paid-claim conversion work, regulatory and launch uncertainty for sHTG, glycemic-control findings and unresolved safety and dosing questions for ARO-DIMER-PA.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management is preparing for a potential U.S. launch of REDEMPLO in sHTG in the second quarter of 2027, subject to successful FDA review and approval, with the sNDA expected to receive a PDUFA date over the next 50 days or so under STAR’s 6-month priority review framework; it continues to see $3 billion to $4 billion in annual U.S. sales over time in sHTG, targeting an initial population of almost 1 million people, including patients with triglycerides at or above 880 milligrams per deciliter or above 500 milligrams per deciliter with a prior history of pancreatitis, supported by a current U.S. wholesale acquisition cost of $45,000 per patient per year and more than 20,000 health care professionals identified as likely sHTG treaters. The company expects to report additional obesity data before the end of the year, additional ARO-DIMER-PA data around mid-2027, the 70 Phase III readout in HoFH in the second half of 2027, a zodasiran NDA filing by the end of 2027, and initial patient data from ARO-MAPT in the second half of 2027; it is targeting CTAs for 2 wholly-owned CNS candidates around end of 2026 or early '27 and additional CNS clinical entries by the end of 2027. Management said it is too early to provide financial guidance.
Arrowhead Pharmaceuticals Risk Analysis
Arrowhead Pharmaceuticals disclosed 67 risk factors in its most recent earnings report. Arrowhead Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksArrowhead Pharmaceuticals Peers Comparison
Overall Rating
SRPT60Neutral
NTLA49Neutral
STOK46Neutral
DYN44Neutral
IONS42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 60Neutral | $1.72B | 178.56 | 1.04% | ― | -18.95% | 59.85% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $1.36B | -2.90 | -64.73% | ― | -8.07% | 21.55% | |
| 46Neutral | $1.75B | -7.04 | -67.30% | ― | -86.28% | -634.38% | |
| 44Neutral | $3.22B | -4.73 | -69.73% | ― | ― | 0.69% | |
| 42Neutral | $4.84B | -8.75 | -120.44% | ― | -0.79% | -106.48% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:HDP1 | Arrowhead Pharmaceuticals, Inc. | 42.99 | 8.36 | 24.14% | |
| IONS | Ionis Pharmaceuticals Inc. | 29.06 | -44.20 | -60.33% | |
| SRPT | Sarepta Therapeutics Inc. | 16.07 | -1.47 | -8.38% | |
| NTLA | Intellia Therapeutics Inc | 9.70 | 1.22 | 14.39% | |
| STOK | Stoke Therapeutics | 26.68 | -0.27 | -1.00% | |
| DYN | Dyne Therapeutics, Inc. | 17.16 | -3.08 | -15.22% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
